AtonRa Partners Sells 796 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

AtonRa Partners reduced its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 9.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,498 shares of the company’s stock after selling 796 shares during the period. AtonRa Partners’ holdings in 10x Genomics were worth $420,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. SVB Wealth LLC raised its position in shares of 10x Genomics by 92.1% during the fourth quarter. SVB Wealth LLC now owns 1,446,552 shares of the company’s stock valued at $80,949,000 after buying an additional 693,422 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its stake in 10x Genomics by 32.9% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,283,530 shares of the company’s stock valued at $127,786,000 after acquiring an additional 565,059 shares during the period. Bleakley Financial Group LLC acquired a new position in 10x Genomics in the 4th quarter valued at approximately $234,000. ARK Investment Management LLC lifted its position in shares of 10x Genomics by 35.0% in the 4th quarter. ARK Investment Management LLC now owns 4,041,287 shares of the company’s stock worth $226,150,000 after acquiring an additional 1,047,827 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of 10x Genomics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 8,903,517 shares of the company’s stock worth $367,270,000 after purchasing an additional 354,921 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other 10x Genomics news, CEO Serge Saxonov sold 1,000 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $49.53, for a total value of $49,530.00. Following the completion of the sale, the chief executive officer now owns 855,381 shares in the company, valued at approximately $42,367,020.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other 10x Genomics news, CEO Serge Saxonov sold 1,000 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $49.53, for a total transaction of $49,530.00. Following the transaction, the chief executive officer now owns 855,381 shares of the company’s stock, valued at approximately $42,367,020.93. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Justin J. Mcanear sold 1,865 shares of 10x Genomics stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total value of $86,424.10. Following the completion of the sale, the chief financial officer now directly owns 95,240 shares of the company’s stock, valued at $4,413,421.60. The disclosure for this sale can be found here. Insiders have sold a total of 12,959 shares of company stock worth $592,806 in the last 90 days. Corporate insiders own 10.65% of the company’s stock.

10x Genomics Stock Performance

10x Genomics stock traded up $0.81 during trading hours on Monday, hitting $28.40. 1,458,752 shares of the stock were exchanged, compared to its average volume of 1,472,868. The stock has a market capitalization of $3.38 billion, a P/E ratio of -13.24 and a beta of 1.90. The business’s 50-day moving average is $37.70 and its two-hundred day moving average is $42.54. 10x Genomics, Inc. has a 12 month low of $26.30 and a 12 month high of $63.57.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, February 15th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). 10x Genomics had a negative return on equity of 28.82% and a negative net margin of 41.17%. The business had revenue of $183.98 million for the quarter, compared to the consensus estimate of $182.73 million. During the same quarter last year, the company earned ($0.15) earnings per share. The firm’s revenue was up 17.8% on a year-over-year basis. On average, equities analysts predict that 10x Genomics, Inc. will post -1.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Barclays cut their target price on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, April 10th. Stifel Nicolaus reduced their price objective on shares of 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a report on Friday, February 16th. Canaccord Genuity Group lowered their target price on shares of 10x Genomics from $65.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft cut their price target on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, April 18th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $58.00.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.